Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer. Recent ...

The study found that patients with luminal B subtype prostate cancer benefited from the addition of hormone therapy to ...

Until about 15 years ago, most men diagnosed with prostate cancer — no matter how aggressive — underwent surgery or radiation ...

Prostate cancer is one of the most common cancers affecting men in the United States, and it comes with a heavy price tag. Nearly 300,000 men are expected to be diagnosed this year, and treatment ...

(Nasdaq: VCYT), a leading genomic diagnostics company, announced that new data from the prospective, randomized integral biomarker BALANCE trial (NCT03371719) finds that the PAM50 molecular signature ...

At ASTRO, Artera presented clinical validation data on its prostate cancer test in an Asian population,and showed how the test may complement gene expression-based approaches.

Discover a study on focal therapy for prostate cancer, showing how the Decipher genomic score predicts treatment success and ...

Researchers at the Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University have preliminarily validated an artificial intelligence (AI) tool to predict ...

In the modern era of advanced imaging and genomics testing, the digital rectal exam (DRE) is still an "important" and clinically relevant prognostic test for prostate cancer, conclude the authors of a ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

This undated microscope image provided by the National Institutes of Health shows cancer cells with the cell nuclei stained red. The U.S. Food and Drug Administration approved the use of Paige ...

Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...